Clinical Trial

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-11-17; most recent amendment 2026-05-21.
Status change: Not Yet Recruiting → Recruiting 2025-12-09
Trial Details
NCT Number NCT07246564
Lead Sponsor UCB Biopharma SRL
Conditions Myasthenia Gravis
Enrollment 40 participants
Start Date 2025-12-01
Primary Completion 2027-10-15 (estimated)
Study Completion 2027-10-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-22